Page 271 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 271
P0869 EARLY VERSUS DELAYED USE OF SOFOSBUVIR ePOSTERS
P0870 PLUS PEGINTERFERON/RIBAVIRIN THERAPY IN
P0871 FIBROSIS PATIENTS WITH HEPATITIS C VIRUS: A COST-
P0872 EFFECTIVENESS ANALYSIS
P0873 María Buti*, Raquel Domínguez-Hernández, Itziar Oyagüez,
Magdalena Rueda, Miguel Ángel Casado, Spain
ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS
OF TREATMENT WITH DACLATASVIR+SOFOSBUVIR
IN PATIENTS CHRONICALLY INFECTED WITH HCV
GENOTYPE 3
Phil McEwan*, Thomas Ward, Samantha Webster, Anupama Kalsekar,
Michael Brenner,Yong Yuan, The United Kingdom
REAL LIFE EXPERIENCE WITH INTERFERON/RIBAVIRIN-
FREE ANTIVIRAL TREATMENT IN RENAL TRANSPLANT
RECIPIENTS AND ENDSTAGE RENAL DISEASE-PATIENTS
ON DIALYSIS INFECTED WITH HEPATITIS C VIRUS
Sandra Beinhardt*, Karin Kozbial, Alice Schmidt, Clarissa Freissmuth,
Mattias Mandorfer, Robert Strassl, Ramon al Zoairy, Rudolf Stauber,
Michael Strasser, G. Sunder-Plassmann, Michael Trauner, Markus Peck-
Radosaljevic, Wolfgang Vogel, Harald Hofer, Peter Ferenci, Austria
EARLY VIRAL KINETICS DO NOT DIFFER IN PATIENTS
WITH VARYING DEGREES OF FIBROSIS AND CIRRHOSIS IN
THE SOLAR 1 TRIAL
Tania W. Welzel*, K. R. Reddy, Steven L. Flamm, Jill Denning,
Sarah Arterburn, Theo Brandt-Sarif, Phillip S. Pang,
John G. McHutchison, Michael Charlton, Gregory T. Everson,
Steven Zeuzem, Nezam Afdhal, Germany
OMBITASVIR/PARITAPREVIR/RITONAVIR AND
DASABUVIR WITH RIBAVIRIN (RBV) HAS MINIMAL
IMPACT ON HEALTH-RELATED QUALITY OF LIFE
(HRQOL) COMPARED WITH PLACEBO DURING 12-WEEK
TREATMENT IN TREATMENT-NAÏVE ADULTS WITH
CHRONIC HEPATITIS C (CHC)
Yan Liu*, Lois Larsen, Stefan Zeuzem, Eoin Coakley, Robert Baran,
Timothy Juday, The United States
Vienna, Austria • April 22–26, 2015 271
P0870 PLUS PEGINTERFERON/RIBAVIRIN THERAPY IN
P0871 FIBROSIS PATIENTS WITH HEPATITIS C VIRUS: A COST-
P0872 EFFECTIVENESS ANALYSIS
P0873 María Buti*, Raquel Domínguez-Hernández, Itziar Oyagüez,
Magdalena Rueda, Miguel Ángel Casado, Spain
ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS
OF TREATMENT WITH DACLATASVIR+SOFOSBUVIR
IN PATIENTS CHRONICALLY INFECTED WITH HCV
GENOTYPE 3
Phil McEwan*, Thomas Ward, Samantha Webster, Anupama Kalsekar,
Michael Brenner,Yong Yuan, The United Kingdom
REAL LIFE EXPERIENCE WITH INTERFERON/RIBAVIRIN-
FREE ANTIVIRAL TREATMENT IN RENAL TRANSPLANT
RECIPIENTS AND ENDSTAGE RENAL DISEASE-PATIENTS
ON DIALYSIS INFECTED WITH HEPATITIS C VIRUS
Sandra Beinhardt*, Karin Kozbial, Alice Schmidt, Clarissa Freissmuth,
Mattias Mandorfer, Robert Strassl, Ramon al Zoairy, Rudolf Stauber,
Michael Strasser, G. Sunder-Plassmann, Michael Trauner, Markus Peck-
Radosaljevic, Wolfgang Vogel, Harald Hofer, Peter Ferenci, Austria
EARLY VIRAL KINETICS DO NOT DIFFER IN PATIENTS
WITH VARYING DEGREES OF FIBROSIS AND CIRRHOSIS IN
THE SOLAR 1 TRIAL
Tania W. Welzel*, K. R. Reddy, Steven L. Flamm, Jill Denning,
Sarah Arterburn, Theo Brandt-Sarif, Phillip S. Pang,
John G. McHutchison, Michael Charlton, Gregory T. Everson,
Steven Zeuzem, Nezam Afdhal, Germany
OMBITASVIR/PARITAPREVIR/RITONAVIR AND
DASABUVIR WITH RIBAVIRIN (RBV) HAS MINIMAL
IMPACT ON HEALTH-RELATED QUALITY OF LIFE
(HRQOL) COMPARED WITH PLACEBO DURING 12-WEEK
TREATMENT IN TREATMENT-NAÏVE ADULTS WITH
CHRONIC HEPATITIS C (CHC)
Yan Liu*, Lois Larsen, Stefan Zeuzem, Eoin Coakley, Robert Baran,
Timothy Juday, The United States
Vienna, Austria • April 22–26, 2015 271
